Arcadia Biosciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Thomas Schaefer
Chief executive officer
US$499.5k
Total compensation
| CEO salary percentage | 52.05% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Zola Distribution Expansion Will Unlock Enduring Market Strength
Arcadia's focus on expanding Zola distribution and profitable product lines is set to drive revenue growth and improve earnings through high-margin sales.We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely
Mar 01
Arcadia Biosciences to raise $5M in securities offering
Aug 15Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings
Nov 29We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit
Nov 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$771k |
| Dec 31 2024 | US$499k | US$260k | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$731k |
| Jun 30 2024 | n/a | n/a | -US$190k |
| Mar 31 2024 | n/a | n/a | US$3m |
| Dec 31 2023 | US$382k | US$260k | -US$5m |
Compensation vs Market: Thomas's total compensation ($USD499.48K) is about average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
CEO
Thomas Schaefer (48 yo)
Mr. Thomas J. Schaefer serves as Chief Executive Officer and President of Arcadia Biosciences, Inc. from July 03, 2024 and is its Director since August 1, 2024. He served as Chief Financial Officer of Arca...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$499.48k | 0.21% $ 13.1k | |
| Independent Director | 7.9yrs | US$90.97k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$92.47k | 0.016% $ 997.0 | |
| Independent Director | 7yrs | US$72.97k | 0% $ 0 | |
| Independent Chair of the Board | 8.6yrs | US$153.44k | 0.037% $ 2.3k | |
| Independent Director | 7.9yrs | US$88.97k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$83.47k | 0% $ 0 |
Experienced Board: RKDA's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 05:35 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcadia Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Klieve | Lake Street Capital Markets, LLC |
| Jon Ritzenthaler | Piper Sandler Companies |
| Brett William Wong | Piper Sandler Companies |